MX2019000508A - Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1). - Google Patents

Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1).

Info

Publication number
MX2019000508A
MX2019000508A MX2019000508A MX2019000508A MX2019000508A MX 2019000508 A MX2019000508 A MX 2019000508A MX 2019000508 A MX2019000508 A MX 2019000508A MX 2019000508 A MX2019000508 A MX 2019000508A MX 2019000508 A MX2019000508 A MX 2019000508A
Authority
MX
Mexico
Prior art keywords
imaging
radioligands
ido1 enzyme
ido1
enzyme
Prior art date
Application number
MX2019000508A
Other languages
English (en)
Spanish (es)
Inventor
Huang Audris
Aaron Balog James
j donnelly David
Lee COLE Erin
Charles BURRELL Richard
A Turley Wesley
J Allentoff Alban
Arthur WALLACE Michael
Skinbjerg Mette
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2019000508A publication Critical patent/MX2019000508A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Quinoline Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2019000508A 2016-07-19 2017-07-18 Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1). MX2019000508A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364020P 2016-07-19 2016-07-19
PCT/US2017/042510 WO2018017529A1 (en) 2016-07-19 2017-07-18 Radioligands for imaging the ido1 enzyme

Publications (1)

Publication Number Publication Date
MX2019000508A true MX2019000508A (es) 2019-03-28

Family

ID=59416832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000508A MX2019000508A (es) 2016-07-19 2017-07-18 Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1).

Country Status (13)

Country Link
US (2) US20190282714A1 (enExample)
EP (1) EP3487516A1 (enExample)
JP (1) JP6987840B2 (enExample)
KR (1) KR102513886B1 (enExample)
CN (1) CN109475594A (enExample)
AU (1) AU2017298262B2 (enExample)
BR (1) BR112019000499A2 (enExample)
CA (1) CA3031079A1 (enExample)
EA (1) EA039877B1 (enExample)
IL (1) IL264187B (enExample)
MX (1) MX2019000508A (enExample)
SG (1) SG11201900336YA (enExample)
WO (1) WO2018017529A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528300A (ja) * 2016-08-26 2019-10-10 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company インドールアミン2,3−ジオキシゲナーゼの阻害剤およびその使用方法
WO2019006292A1 (en) * 2017-06-30 2019-01-03 Bristol-Myers Squibb Company SUBSTITUTED QUINOLINYCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED PROCESSES FOR THE PREPARATION THEREOF
KR20200088410A (ko) * 2017-11-21 2020-07-22 광동 오포 모바일 텔레커뮤니케이션즈 코포레이션 리미티드 정보 전송 방법, 네트워크 디바이스 및 단말기 디바이스
EP3720843A1 (en) * 2017-12-05 2020-10-14 GlaxoSmithKline Intellectual Property Development Limited Modulators of indoleamine 2,3-dioxygenase
CN110357813A (zh) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
AR120935A1 (es) * 2020-01-02 2022-03-30 Hutchison Medipharma Ltd Derivados de amida y usos de los mismos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182359A (zh) * 2007-11-09 2008-05-21 中山大学 人吲哚胺2,3-双加氧酶多克隆抗体及其制备方法和应用
WO2011109262A2 (en) * 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
WO2016040458A2 (en) * 2014-09-09 2016-03-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen

Also Published As

Publication number Publication date
BR112019000499A2 (pt) 2019-04-24
US20190282714A1 (en) 2019-09-19
US20220305144A1 (en) 2022-09-29
JP2019527225A (ja) 2019-09-26
AU2017298262B2 (en) 2024-07-18
IL264187A (en) 2019-02-28
CA3031079A1 (en) 2018-01-25
KR102513886B1 (ko) 2023-03-27
WO2018017529A1 (en) 2018-01-25
KR20190030727A (ko) 2019-03-22
AU2017298262A1 (en) 2019-03-07
EP3487516A1 (en) 2019-05-29
CN109475594A (zh) 2019-03-15
EA201990198A1 (ru) 2019-06-28
JP6987840B2 (ja) 2022-01-05
SG11201900336YA (en) 2019-02-27
IL264187B (en) 2021-06-30
EA039877B1 (ru) 2022-03-23

Similar Documents

Publication Publication Date Title
MX2019000508A (es) Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1).
HUS2200011I1 (hu) Készítmények és eljárások HAO1 (hidroxisav-oxidáz-1 (glikolát-oxidáz)) gén expressziójának gátlására
ZA201906822B (en) Indole ahr inhibitors and uses thereof
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
ZA201903984B (en) Methods of using thermostable serine proteases
GEP20207151B (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
PH12018500397A1 (en) Compounds and compositions useful for treating disorders related to ntrk
SG10201902813XA (en) Methods and materials for biosynthesis of mogroside compounds
PH12015502048A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
SG10202102897PA (en) Compositions and methods for the depletion of cd137+ cells
EA039598B9 (ru) Соединение, нацеленное на ил-23а и фно-альфа, и его применение
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
NZ725917A (en) Novel polymerase-i inhibitors, uses and methods for making them
MX375892B (es) Composición que comprende sal de glutamato de acilo como tensoactivo principal o tensoactivo principal aniónico
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2023012628A (es) Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales.
MX2018016037A (es) Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa.
MX2018007083A (es) Sintesis diaestereoselectiva de derivados de fosfato y del profarmaco de gemcitabina nuc-1031.
WO2016079110A3 (en) Use of enzyme for cleaning
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
SG11202012762WA (en) Methods and compositions for cluster generation by bridge amplification
IN2014DN00254A (enExample)
MX388832B (es) Deteccion especifica de isoformas de clusterina.
MX2016009056A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.